Kornimate/medical-research-clean huggingface dataset:
evaluation of kinesophobia in patients with metabolic syndrome

Conditions: Kinesiophobia; Metabolic Syndrome

Summary: metabolic syndrome (ms) is a public health problem characterized by central obesity, increased blood pressure and triglyceride levels, decreased blood hdl levels and the presence of insulin resistance (1).kinesiophobia is a fear of irrational movement that develops because of its belief in susceptibility to injury and is associated with low levels of physical activity. considering that exercise improves metabolic processes in people with ms, we aimed to evaluate the presence of kinesophobia in patients with ms. patients aged 45-65 years diagnosed with metabolic syndrome and healthy controls will be included in the study. patients with rheumatic and neurological diseases,history of trauma, gonarthrosis, lumbar disc hernia, previous fractures, fibromyalgia and those who have experienced pain for the last week will be excluded. the participants will be filled in the short form-36 (sf-36), the hospital anxiety and depression scale, and the tampa kinesiophobia scale. 48 patients with ms and 48 healthy participants will be included in the study.


Eligibility criteria:
inclusion criteria: * patients with metabolic syndrome exclusion criteria: * patients with rheumatic disease * patients with neurologic disease * patients with history of trauma * patients with gonartrosis * pateints with fibromialgia

Keywords: kinesiophobia metabolic syndrome exercise
comparison of dexmedetomidine and remifentanil for postoperative pain in transphenoidal pituitary surgery

Conditions: Postoperative Pain

Summary: in patients with pituitary adenoma scheduled for endoscopic transsphenoidal pituitary surgery, it was aimed to compare the efficacy of postoperative pain relief of a selective α-2 agonist "dexmedetomidine" and the rapid and short-acting opioid "remifentanil" using the "numerical rating scale" (nrs) administered alongside propofol in perioperative maintenance anesthesia. .


Eligibility criteria:
inclusion criteria: * 18-65 years old * asa-1 and asa-2 patients exclusion criteria: * patients in need of postoperative intensive care

Keywords: dexmedetomi̇di̇ne remi̇fentanyl pituitary surgery
activate in public housing

Conditions: Pneumonia; Influenza; Varicella Zoster; Meningitis; COVID-19; Vaccine Hesitancy

Summary: this multilevel, multidisciplinary, theoretically based, culturally sensitive, community-engaged intervention sets out to mitigate uptake barriers and non-adherence to vaccination schedules as recommended by the cdc and increase influenza, meningitis, pneumonia, vzv, and covid-19 vaccine rates among under-resourced african american and latino public housing residents in south los angeles.

vaccinations are critical for preventing infectious diseases such as influenza, meningitis, pneumonia, varicella zoster virus (vzv), and covid-19. despite increasing national distribution and promotion of routine recommendations for adult vaccination, coverage remains low, with historically lower uptake among racial and ethnic minorities. this is compounded by higher levels of vaccine hesitancy, which may be attributed to a myriad of issues, including worsening social determinants, medical mistrust, and lack of access to health services. specifically, african american and latino public housing residents may benefit from public health campaigns and vaccination initiatives to support high vaccine uptake and confidence. this r01 proposal seeks to expand on a proven, multilevel, multidisciplinary, theoretically based, culturally sensitive, community-engaged intervention by expanding the academic-community team for improving vaccine acceptability and targeted engagement (activate) program. guided by a fusion of the social-ecological framework (sem) and the practical, robust implementation and sustainability model (prism), the activate program is inclusive of health factors on the individual, interpersonal, community, and societal level and elements for successful implementation. led by leadership triads of public housing resident leaders, nurse practitioner students, and public health students, the activate program centers on mitigating uptake barriers and non-adherence to vaccination schedules as recommended by the cdc and to increase influenza, meningitis, pneumonia, vzv, and covid-19 vaccine rates among under-resourced aa and latino adults in south la.

Eligibility criteria:
aim 3: inclusion criteria: * identify as latinx or african american * age 18 or older * reside in one of the six collaborating public housing area * speak either english or spanish * report vaccine hesitancy exclusion criteria: * not a resident at one of the collaborating public housing areas * does not self-identify as african american or latinx * age 17 and younger * unable to speak either english or spanish * received all recommended vaccines for influenza, pneumonia, meningitis, vzv, and covid-19 * no reporting of vaccine hesitancy
effectiveness of low dose aspirin in gastrointestinal cancer prevention - taiwan

Conditions: Colorectal Neoplasms

Summary: the study evaluates the protective effect of low-dose aspirin use on gastrointestinal cancers (colorectal, esophageal and gastric cancers) in long-term users, episodic users and non-users of aspirin in taiwan.

the primary objective is to investigate the protective effect of long-term low dose use of aspirin on colorectal, esophageal and gastric cancer in adult subjects from taiwan. secondary objectives are to evaluate the protective effect by duration of low-dose aspirin use on colorectal cancer, the effect of discontinuation of aspirin on colorectal cancer prevention, the staging distribution of colorectal cancer and the description of fatal cases due to colorectal cancer. aspirin use will be identified through taiwanese national health insurance (nih) data from 2000 to 2015. cancer cases and staging of the three cancer types will be ascertained through the taiwan cancer registry, using data from 2000 to 2014. fatal cases will be ascertained using mortality database from 2000 to 2015.

Eligibility criteria:
inclusion criteria: * age 40 or older at the cohort entry date. * taiwanese national health insurance enrollees with non-missing and consistent age and gender information. exclusion criteria: * subjects with any cancer diagnosis before cohort entry date. * no use of national health insurance before the cohort entry date. * low dose aspirin prescription before cohort entry date. * subjects with conditions contra-indicated for low dose aspirin use before cohort entry date.

Keywords: low-dose aspirin, cancer prevention
modified hfnc therapy for arf patients undergoing flexible bronchoscopy

Conditions: Acute Hypoxemic Respiratory Failure; High-flow Nasal Cannula Oxygen

Summary: acute respiratory failure (afr) is a serious condition that requires prompt and appropriate intervention to prevent further deterioration and improve outcomes. bronchoscopy is a commonly used diagnostic and therapeutic procedure in patients with respiratory failure. however, traditional low-flow oxygen supplementation during bronchoscopy may not provide adequate oxygenation and ventilation, leading to complications and worsening of the patient's condition. high-flow nasal cannula therapy has improved oxygenation and ventilation in critically ill patients, making it a promising alternative to traditional oxygen supplementation during bronchoscopy. the bronchoscope is passed through the nose during all procedures in our center. hfnc oxygen therapy is applied to both nostrils. the bronchoscope occupies one of the nares receiving oxygen therapy during bronchoscopy. as a result, the application of hfnc needs to be optimized. therefore, the investigators designed a modified hfnc with a single cannula. however, limited data exist on the safety and efficacy of modified hfnc therapy in patients with respiratory failure undergoing bronchoscopy. therefore, the aim of this study is to evaluate the impact of modified hfnc therapy on the outcomes of undergoing bronchoscopy in patients with arf. the findings of this study will contribute to understanding the role of modified hfnc therapy in managing arf and inform clinical practice.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old; 2. bronchoscopy is required; 3. 150 mmhg ≤ pao2/fio2 \< 300 mmhg. exclusion criteria: 1. not tolerate hfnc oxygen therapy; 2. obstruction of nasopharynx cavity; 3. platelet\<60 × 109/l； 4. need tracheal intubation; 5. the patient has received invasive ventilation.
the effect of remote ischemic preconditioning on the ischemic reperfusion injury in infants with ventricular septal defect and pulmonary hypertension

Conditions: Ventricular Septal Defect; Pulmonary Hypertension

Summary: intraoperative myocardial and pulmonary protection is important for better outcome after cardiac surgery. ischemic preconditioning is one of organ protective strategies against ischemia-reperfusion injury by applying brief ischemia to the target organ before a subsequent critical ischemia, and its effect has been confirmed. however, its clinical application is not easy because ischemic insult may aggravate the function of vulnerable organ. on the other hand, remote ischemic preconditioning (ripc) is another protective approach by applying ischemia to other less vulnerable organ such as skeletal muscle before critical ischemia-reperfusion injury to heart. the effect of ripc has been well demonstrated in adults and children. however, little is known about the effect of remote ischemic precondition on the pediatric myocardium to ischemia and reperfusion injury. the effect of ripc on the children remains to be further evaluated because the degree of ischemia-reperfusion injury is different according to age, cardiac pathology and cyanosis. in addition, the previous report on children dealt with a diverse range of congenital heart defects with a wide age range. the purpose of this study was to evaluate the effect of ripc on myocardial and pulmonary protection in infants with pulmonary hypertension who need repair of simple ventricular septal defect.


Eligibility criteria:
inclusion criteria: * perimembranous or muscular outlet or muscular inlet ventricular septal defect * pulmonary hypertension (+) * infant (\<1 year) exclusion criteria: * subarterial ventricular defect * chromosomal defect * airway or parenchymal lung disease * blood disorder * anticipation of cardiac muscle resection

Keywords: ventricular septal defect remote ischemic preconditioning pulmonary hypertension infant with ventricular septal defect and pulmonary hypertension
pre-admission hyperglycemia and its effect on morbidity and mortality

Conditions: Hyperglycemia

Summary: it is currently standard of care in many medical and surgical icu's to institute a nurse driven insulin protocol in maintaining tight glucose control in the critical patient. many articles have been written to address this topic. however, there is no current data regarding the use of glycohemoglobin as a marker of risk of morbidity and mortality. in our study we would like to determine whether or not the hba1c could be used as a marker of morbidity and mortality. the hba1c is a simple blood test that may be added on to any cbc collection tube; a blood sample that critical patients have drawn up to several times a day. the investigators would analyze this information in respect to the rest of the clinical data collected regarding the patient's illness.


Eligibility criteria:
inclusion criteria: * all patients admitted to the medical and surgical icu, and ccu that are 18 year's or older and speak english that give consent.

Keywords: hyperglycemia hga1c mortality
suicide prevention in chinese older adults

Conditions: Suicidal Ideation

Summary: this project aims to develop and refine a suicide intervention protocol, and pilot test a culturally tailored randomized control trial to reduce suicidal thoughts among u.s. chinese older adults. during the first phase of the study, the investigators plan to invite the community advisory board and key stakeholders to participate in the iterative design and refinement of the study protocol. during the second phase of the project and after the initial screening and based on a specific set of inclusion criteria, the investigators will invite u.s. chinese older adult to participate in a pilot randomized control trial of a culturally adapted intervention to reduce the frequency and intensity of suicidal thoughts in chinese older adults. during the third phase of the project, the investigators plan to invite pilot intervention participants as well as key stakeholders and health care professionals on the cultural acceptability of the pilot intervention. through the achievement of these objectives, the investigators will set the foundation to fully test a culturally adapted in-home intervention, which may be particularly suitable for chinese older adults with suicidal thoughts as it addresses cultural-specific barriers and integrates care management within existing community services agencies using non-mental health professionals, including community health workers.


Eligibility criteria:
inclusion criteria: 1. self-identified as chinese 2. \>50 years of age 3. suicidal thoughts within the last month as detected from the item 9 in phq-9 4. no plans to move for 6 months 5. no significant cognitive impairment with chinese mini-mental state examination (c-mmse) score \>20
comparing neoadjuvant/adjuvant gvax vs a mkrasvax given with anti-pd-1 and anti-cd137 for surgically resectable pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to determine the optimal dose of agen2373 that is safe when given in combination with balstilimab and pancreatic gvax whole cell vaccine and evaluate the safety and clinical activity of balstilimab and agen2373 in combination with gvax (arm 1) or mkrasvax (arm 2) in surgically resectable pancreatic adenocarcinoma.


Eligibility criteria:
inclusion criteria: * have a newly diagnosed, biopsy-proven adenocarcinoma of the pancreas. * tumor must be deemed resectable by the study team * patient's acceptance to have a tumor biopsy. * eastern cooperative oncology group (ecog) performance status 0 - 1. * patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures. * women of childbearing potential (wocbp) must have a negative serum pregnancy test. * for both women and men, must use acceptable form of birth control while on study. exclusion criteria: * received any anti-pancreatic cancer therapy (symptomatic therapies are allowed), or any prior anti-cancer immunotherapy. * diagnosed with another cancer whose natural history or treatment could interfere with safety or efficacy assessments on this study. * uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements. * active autoimmune disease. * systemic steroid therapy (\> 10mg daily prednisone equivalent) or immunosuppressive therapy within 14 days of first dose of study drug administration. * active infection requiring systemic therapy. * known history of human immunodeficiency virus (hiv). * active or chronic hepatitis b or hepatitis c. * known active tuberculosis. * history of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases, chronic obstructive pulmonary disease (copd), asthma requiring medication, etc. * prior allogeneic stem cell transplantation or organ transplantation. * any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drug. * received a live vaccine ≤ 28 days before first dose of study drug. * history of severe hypersensitivity reaction to any monoclonal antibody * concurrent participation in another therapeutic clinical study * pregnant or breastfeeding

Keywords: balstilimab agen2373 kras peptide vaccine peptide vaccine poly-iclc gvax cyclophosphamide immunotherapy anti-pd-1 (anti-check point inhibitor) pd-l1 (check point inhibitor) anti-cd137 cancer vaccine pancreatic cancer pancreatic ductal adenocarcinoma (pdac) adenocarcinoma carcinoma pancreas mkrasvax
a study on diagnosis and treatment of end stage liver disease complicated with infection (sesldip study)

Conditions: End Stage Liver Disease; Infection; Spontaneous Bacterial Peritonitis

Summary: spontaneous bacterial peritonitis (sbp) is a common complication of end-stage liver disease due to various causes. the initial anti-infective medication is appropriate and the patient's survival rate is closely related. ascitic fluid bacterial culture takes a long time, the positive rate is low, it is difficult to guide the timely use of antimicrobial drugs, empirical medicine based on evidence-based medicine for sbp in patients with end-stage liver disease is essential. the american college of hepatology and the european society of hepatology recommend the use of third-generation cephalosporins as the first choice of empirical therapy in patients with end-stage liver disease associated with community-acquired sbp. patients with merger of hospital-acquired sbp with piperacillin / tazobactam or carbapenem +/- glycopeptide antibiotics is the first choice for empirical medication. there is no clear recommendation in china. in recent years, the conclusions of international clinical research in this area have been in disagreement with the recommendations. as a key factor in the selection of empirical antibiotics is local bacterial resistance data, these findings are difficult to evidence-based medicine for chinese doctors. this project intends to observe the efficacy of different initial anti-infective regimens in chinese patients with end-stage liver disease with sbp and 30-day and 60-day non-liver transplant survival rates, providing evidence-based medical evidence for the empirical use of such patients.


Eligibility criteria:
inclusion criteria: 1. meet the end-stage liver disease part of the type of standard (including slow plus acute liver failure, chronic liver failure, cirrhosis decompensation); 2. age\> 18 years old 3. ascites nucleated cell count\> 250 × 106 / l; 4. unable to obtain ascites specimens or ascites nucleated cells count does not meet the conditions of 3) are required abdominal examination tenderness (+), rebound tenderness (+), abdominal ultrasound can detect ascites, and procalcitonin (pct) \> 0.5ng / ml, hs-crp\> 10ng / ml exclusion criteria: 1. history of abdominal surgery within 4 weeks; 2. secondary peritonitis; 3. tuberculous peritonitis; 4. malignant tumor; 5. patients who use hormones or immunosuppressants; 6. aids patients; 7. heart failure or respiratory failure; 8. merge other parts of the infection; 9. died within 48h; 10. liver transplantation during observation; 11. diagnosis of spontaneous bacterial peritonitis is the use of carbapenems or third-generation cephalosporins / enzyme inhibitors, piperacillin / enzyme inhibitor antibiotics
vitamin d, insulin resistance, and cardiovascular disease

Conditions: Vitamin D Deficiency; Insulin Resistance; Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension

Summary: in recent years, vitamin d has been shown not only to be important for bone and calcium metabolism but also for homeostasis of critical tissues involved in vascular disease in patients with diabetes. epidemiological studies indicated the high prevalence of vitamin d deficiency among type 2 dm patients and suggest an increased risk of cardiovascular disease and hypertension with low vitamin d levels. the objective of this proposal is to evaluate the effects of vitamin d replacement on blood pressure control and vascular disease in vitamin d deficient hypertensive patients with diabetes

this is a double blinded, placebo controlled trial. patients who meet the inclusion criteria will be randomized to placebo or 25(oh)d3, 4,000 iu/d orally for 16 weeks. enrolled patients will be tested for 24h-blood pressure, brachial arterial blood flow, vascular inflammatory markers and macrophage inflammatory response to modified-lipoproteins at baseline, middle and at the end of the study.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * 25 (oh) vitamin d levels \< 25 ng/ml * age 25 to 80 years * not on insulin for diabetes treatment * hba1c 5.5% -9.5% * mild/moderately increased blood pressure (systolic 120-160, diastolic 80-100) off bp medications exclusion criteria: * pregnancy * patients with systolic \>160 or diastolic \>100 mmhg * high urine calcium or history of recurrent kidney stones * cardiovascular disease * stage 3 or worse chronic kidney disease

Keywords: vitamin d insulin resistance type 2 diabetes mellitus cardiovascular disease
the effects of programmed death-ligand 1 on postoperative pain for lung cancer patients

Conditions: Lung Cancer; Postoperative Pain

Summary: the concentration of plasma programmed death-ligand 1(pd-l1) for lung cancer patients before video-assisted thoracoscopic surgery is detected. according to the distribution of plasma concentration, patients are divided into high or low expression of pd-l1. differences in acute and chronic postoperative pain are compared between two groups of patients. and effects of pd-l1 expresion on postoperative pain in lung cancer patients are explained.

chronic pain after video-assisted thoracoscopic surgery (vats) has been a major concern for lung cancer patients. the relationship between plasma programmed cell death ligand-1 (pd-l1) concentration and chronic pain in post-vats is uncertain. this study aims to explore the effects of pd-l1 levels on chronic pain and provide proactive pain management regimen according to individual genetic differences. the concentration of plasma pd-l1 for lung cancer patients before video-assisted thoracoscopic surgery is detected. according to the distribution of plasma concentration, patients are divided into high or low expression of pd-l1. differences in acute and chronic postoperative pain are compared between two groups of patients. and effects of pd-l1 expresion on postoperative pain in lung cancer patients are explained.

Eligibility criteria:
inclusion criteria: 1. american society of anesthesiologists physical status i-iv (males and females). 2. 18-80 years of age. 3. patients undergoing video-assisted thoracoscopic surgery for malignant lung disease. exclusion criteria: 1. history of opioid abuse. 2. known psychiatric disorders. 3. unexpected conversion to thoracotomy or transferred to intensive care unit for further treatment. 4. combined with other surgeries or sites.
to demonstrate the superior efficacy of nyc 0462 ointment over that of the placebo in the treatment of plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the aim of this trial is to assess the efficacy of nyc-0462 ointment in the treatment of plaque psoriasis.treatment medication will be administered as follows: a thin layer of study product will be applied to the affected skin, excluding the face, once daily, at approximately the same time daily.


Eligibility criteria:
inclusion criteria: * diagnosis of stable, symptomatic plaque psoriasis * good health with the exception of psoriasis * % bsa and plaque elevation requirements exclusion criteria: * subjects who are pregnant, nursing or planning a pregnancy within the study participation period. * subjects who have any systemic or dermatological disorders with the exception of psoriasis